These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2573987)

  • 21. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dystonia musculorum deformans. Favorable effect of bromocriptine].
    Gautier JC; Awada A
    Rev Neurol (Paris); 1983; 139(6-7):449-50. PubMed ID: 6612149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopa-responsive dystonia: clinical, genetic, and biochemical studies].
    Furukawa Y
    Rinsho Shinkeigaku; 2006 Jan; 46(1):19-34. PubMed ID: 16541791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment with levodopa in a family with autosomal dominant torsion dystonia.
    de Yebenes JG; Moskowitz C; Fahn S; Saint-Hilaire MH
    Adv Neurol; 1988; 50():101-11. PubMed ID: 3400489
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment and prognosis of the therapeutic effect of L-DOPA in dystonia musculorum deformans].
    Mel'nichuk PV; Minich LN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(8):1002-6. PubMed ID: 484133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopa responsive dystonia in a girl with vitiligo.
    Chaudhary N; Mani J; Rawat S; Mulye R; Shah P
    Indian Pediatr; 1998 Jul; 35(7):663-5. PubMed ID: 10216678
    [No Abstract]   [Full Text] [Related]  

  • 28. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia.
    Hoffmann GF; Assmann B; Bräutigam C; Dionisi-Vici C; Häussler M; de Klerk JB; Naumann M; Steenbergen-Spanjers GC; Strassburg HM; Wevers RA
    Ann Neurol; 2003; 54 Suppl 6():S56-65. PubMed ID: 12891655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis.
    Oren DA; Moul DE; Schwartz PJ; Wehr TA; Rosenthal NE
    J Clin Psychopharmacol; 1994 Jun; 14(3):196-200. PubMed ID: 8027416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Characteristics of the clinical course, pathogenesis and treatment of torsion dystonia in childhood].
    Markova ED
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(8):32-5. PubMed ID: 2588895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug therapy of dystonia musculorum deformans].
    Jovicić A; Dordević D
    Vojnosanit Pregl; 1981; 38(1):45-7. PubMed ID: 7245665
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical presentations of dopa-responsive dystonia.
    Bandmann O; Marsden CD; Wood NW
    Adv Neurol; 1998; 78():283-90. PubMed ID: 9750924
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiparkinsonian activity of a single oral dose of PHNO.
    Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
    Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 38. [The differentiated treatment of dystonia musculorum deformans in children].
    Mal'mberg SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1993; 93(5):33-6. PubMed ID: 7908772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.